07 January 2025
07 January 2025
The decision follows a positive recommendation received from the Committee for Medicinal Products for Human Use (CHMP) in November 2024.
Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.
GlobalData expects that the US will contribute the most to the growth of the heart failure market due to the higher prevalence of the condition in this market.
Sentynl took over the therapy’s development and commercialisation from Fortress Biotech's subsidiary Cyprium Therapeutics.
The therapy entered the Phase II SYNAPSE-CMT trial in November 2024.
The ODD was awarded following positive outcomes from a randomised Phase Ib/II clinical study.
The Series A funding round was led by New Enterprise Associates (NEA) with participation from new investors, including Eli Lilly.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
